BAUSCH HEALTH COS INC
BHCNYSETrading Snapshot
- Day Range
- $6.25 β $6.95
- 52-Week Range
- $4.33 β $8.00
- Volume (shares)
- 7,995,569
- Avg Volume (shares)
- β
- Shares Outstanding
- 374.0M
- Next Earnings
- 2026-10-28
Fundamentals Snapshot
- Annual Revenue
- $10.27B
- Last Q Revenue
- $2.85B
- P/E Ratio
- -2.0
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-2.26
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β0.4%
BAUSCH HEALTH COS INC
BHCAbout BAUSCH HEALTH COS INC
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of Octo

Bausch Health Announces US$50 Million Share Repurchase Program
LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its c

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1Β basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of